Mounjaro®
Starting from £179.99/mo
Start journey Learn moreYes, Wegovy does have side effects — and most of them centre on the digestive system. Nausea is the most commonly reported, affecting a significant proportion of people during the early weeks of treatment. That said, the reality is more manageable than many patients fear before they start. Wegovy (semaglutide) is a prescription-only medicine, and every person's experience is assessed individually by a clinician before treatment begins. Understanding what side effects are likely, which are temporary, and which need prompt medical attention makes a real difference to how confidently you approach treatment. Our page on the full profile of Wegovy side effects covers the clinical picture in detail; this page focuses on separating the misconceptions from the facts.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The most common thing people get wrong about Wegovy's side effect profile is assuming the nausea is severe and permanent. It isn't, for the majority of patients. The STEP 1 trial (which involved adults with obesity taking semaglutide 2.4mg over 68 weeks and is the foundational evidence behind Wegovy's UK licence) did record nausea as the most frequently reported symptom, but most participants who experienced it described it as mild to moderate and time-limited. The proportion of people who experience side effects from Wegovy is a reasonable question, and the honest answer is: many people notice something in the early weeks, but relatively few stop treatment because of it.
The graduated dose schedule exists precisely because of this. Treatment begins at 0.25mg, a dose that gives your body time to adjust before the therapeutic doses are reached. Starting low is not a compromise; it is a deliberate clinical strategy to reduce how strongly the GI effects hit. People who try to rush titration, or who access semaglutide from sellers operating without a prescription, often have a much rougher experience because this careful stepping is skipped.
The other misconception worth correcting early is that all side effects carry equal weight. Most are nuisances. A small number are genuine medical signals. Knowing which is which is the practical point of this page, and it is something our prescribers cover as part of every consultation at nume.
The side effects most people encounter fall into a recognisable pattern: nausea, sometimes vomiting, loose stools or constipation, indigestion, reflux, and burping. Fatigue and headache are also reported, particularly in the first few weeks. Injection-site reactions (mild redness or discomfort at the point of the jab) are possible but generally minor. The question of whether Wegovy produces fewer side effects than other treatments is worth exploring if you are weighing options, though comparisons depend heavily on the individual.
Timing matters. These effects tend to cluster around dose increases. A patient who tolerates 0.5mg comfortably might find the step to 1.0mg brings a few uncomfortable days, then things settle again. That rhythm is fairly predictable, which makes it manageable. Keeping a glass of water by the bed, eating smaller meals, and avoiding heavy or fatty foods around injection day are practical steps many patients find genuinely helpful. One thing our prescribers hear often is that people worried most about nausea before they started and found it far less disruptive than expected once they were actually on treatment.
The more acute bowel symptoms that some patients report are less common and usually short-lived, but they are real and worth knowing about, particularly because dehydration can follow severe diarrhoea or vomiting, and dehydration on GLP-1 treatment can, in rare cases, put strain on the kidneys. Staying hydrated and telling your prescriber quickly if GI symptoms are severe is always the right call. The longer-term side effect picture is a separate question and one the evidence is still building on.
This section matters more than any other on this page. A small number of Wegovy side effects require prompt medical attention and should not be waited out. The MHRA's January 2026 Drug Safety Update on GLP-1 medicines specifically highlighted acute pancreatitis: severe stomach pain that doesn't ease, particularly pain that spreads through to the back, with or without vomiting, is a signal to seek urgent care. Do not assume it is ordinary indigestion.
Other situations that need prompt attention include symptoms of a gallbladder problem (upper-right abdominal pain, fever, yellowing of the skin or whites of the eyes), signs of a serious allergic reaction (swelling of the face, lips or throat, difficulty breathing, widespread rash), and any rapid deterioration from severe vomiting or diarrhoea that prevents you keeping fluids down. Heart rate changes (a noticeable, persistent increase) should also prompt a call to your GP or 111.
Mental health signals deserve mention. If you notice low mood, thoughts of self-harm, or a significant shift in how you're feeling emotionally, speak to your GP. The causal picture is not fully established, but it is taken seriously. The NHS patient information for semaglutide lists the full set of symptoms that warrant medical contact; it is worth reading before you start, not only when something feels wrong. If you suspect a side effect, you can also report it directly through the MHRA Yellow Card scheme, patients can submit reports themselves, and it is genuinely how the regulator picks up emerging safety signals.
Some people face a higher side effect burden (or genuine contraindications) that a proper clinical assessment should catch before any prescription is issued. A personal or family history of medullary thyroid carcinoma or MEN2 syndrome, a history of pancreatitis, or certain gastrointestinal conditions are among the factors a prescriber needs to know about. Wegovy is not recommended during pregnancy, while breastfeeding, or for anyone trying to conceive. It is not licensed for use in those under 18.
This is why the prescriber review that precedes every legitimate Wegovy prescription is not a formality. At nume, a GPhC-registered Independent Prescriber (a named clinician, not a decision algorithm) reads every consultation before any treatment is approved. That review is where your medical history, current medicines, and individual risk factors are weighed against the potential benefit. If you are already on Wegovy and have questions about how your side effects are being managed, our support team is available seven days a week. For those still at the research stage, our Wegovy treatment overview covers the full picture, and you can explore all available weight-loss options on our treatment options page before starting a free consultation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.